Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

FDA PMA

Multi-analyte test system with algorithmic analysis for detection of prostate cancer

PMA Number: P200048 · 2025-11-28

Decision Date2025-11-28
PMA NumberP200048
Product CodeQRF
Device ClassClass 3
Medical SpecialtyU
Advisory CommitteeIM

Device Summary

Multi-analyte test system with algorithmic analysis for detection of prostate cancer is a medical device manufactured by Cleveland Diagnostics, Inc.. It received FDA Premarket Approval (PMA) on 2025-11-28 under PMA number P200048. The device is classified under FDA product code QRF. It was reviewed by the IM advisory panel. This device is classified as Class III by the FDA. Class III devices subject to the most stringent regulatory controls. These devices generally require premarket approval (PMA) because they support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. PMA is the most stringent type of device marketing application required by the FDA. The device falls under the medical specialty of U. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to submit clinical trial data demonstrating the safety and effectiveness of the device. PMA is generally required for Class III devices that support or sustain human life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury.

Frequently Asked Questions

What is Multi-analyte test system with algorithmic analysis for detection of prostate cancer?

Multi-analyte test system with algorithmic analysis for detection of prostate cancer is a medical device that received FDA Premarket Approval (PMA) on 2025-11-28. It is manufactured by Cleveland Diagnostics, Inc.. The PMA number is P200048.

When did Multi-analyte test system with algorithmic analysis for detection of prostate cancer receive FDA PMA approval?

Multi-analyte test system with algorithmic analysis for detection of prostate cancer received FDA PMA approval on 2025-11-28, under approval number P200048.

What company makes Multi-analyte test system with algorithmic analysis for detection of prostate cancer?

Multi-analyte test system with algorithmic analysis for detection of prostate cancer is manufactured by Cleveland Diagnostics, Inc..

What is the difference between PMA and 510(k)?

PMA (Premarket Approval) is the FDA process for evaluating Class III medical devices. Unlike 510(k) clearance, which demonstrates substantial equivalence to a predicate device, PMA requires the manufacturer to provide clinical data proving safety and effectiveness. PMA is the most stringent type of device marketing application required by the FDA.

What is the FDA product code for Multi-analyte test system with algorithmic analysis for detection of prostate cancer?

The FDA product code for Multi-analyte test system with algorithmic analysis for detection of prostate cancer is QRF.

What FDA device class is Multi-analyte test system with algorithmic analysis for detection of prostate cancer?

Multi-analyte test system with algorithmic analysis for detection of prostate cancer is classified as Class III by the FDA.

Related Clinical Trials

Related PubMed Literature

Related Devices (Code: QRF)

Official Source

View on FDA Database →

Data sourced from FDA Open API. For the most current and authoritative information, always refer to the official record.